SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Aldeyra Therapeutics, Inc. – ‘S-8’ on 11/3/23 – ‘EX-23.1’

On:  Friday, 11/3/23, at 4:43pm ET   ·   Effective:  11/3/23   ·   Accession #:  1193125-23-270467   ·   File #:  333-275315

Previous ‘S-8’:  ‘S-8’ on 3/9/23   ·   Next & Latest:  ‘S-8’ on 3/7/24   ·   21 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/03/23  Aldeyra Therapeutics, Inc.        S-8        11/03/23    4:118K                                   Donnelley … Solutions/FA

Registration Statement – Securities for an Employee Benefit Plan   —   Form S-8   —   SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     50K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML      8K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 4: EX-FILING FEES  Filing Fees                                     HTML     15K 


‘EX-23.1’   —   Consent of Expert or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-23.1  

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Aldeyra Therapeutics, Inc.

Lexington, Massachusetts

We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-8 of our report dated March 9, 2023, relating to the consolidated financial statements of Aldeyra Therapeutics, Inc. appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

/s/ BDO USA, P.C.

Boston, Massachusetts

November 3, 2023

BDO USA, P.C., a Virginia professional corporation, is the U.S. member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

BDO is the brand name for the BDO network and for each of the BDO Member Firms.


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing    Date    Other Filings
Filed on / Effective on:11/3/2310-Q
3/9/2310-K,  8-K,  S-8
12/31/2210-K,  10-K/A,  ARS
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/07/24  Aldeyra Therapeutics, Inc.        S-8 POS     3/07/24    1:30K                                    Donnelley … Solutions/FA


20 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/03/23  Aldeyra Therapeutics, Inc.        10-Q        9/30/23   66:7.1M                                   Donnelley … Solutions/FA
11/01/23  Aldeyra Therapeutics, Inc.        8-K:1      10/31/23   10:154K                                   Donnelley … Solutions/FA
10/16/23  Aldeyra Therapeutics, Inc.        8-K:8      10/10/23   10:146K                                   Donnelley … Solutions/FA
 8/03/23  Aldeyra Therapeutics, Inc.        10-Q        6/30/23   66:7.8M                                   Donnelley … Solutions/FA
 8/02/23  Alimera Sciences Inc.             8-K:3,5,8,9 8/01/23   15:2.5M
 7/03/23  Aldeyra Therapeutics, Inc.        8-K:5       6/30/23   10:151K                                   Donnelley … Solutions/FA
 6/29/23  Aldeyra Therapeutics, Inc.        8-K:7,8,9   6/29/23   12:3.9M                                   Business Wire/FA
 6/27/23  Aldeyra Therapeutics, Inc.        8-K:7,8,9   6/27/23   12:3M                                     Business Wire/FA
 6/21/23  Aldeyra Therapeutics, Inc.        8-K:8,9     6/21/23   11:181K                                   Business Wire/FA
 6/15/23  Aldeyra Therapeutics, Inc.        8-K:7,8,9   6/15/23   12:4M                                     Business Wire/FA
 5/04/23  Aldeyra Therapeutics, Inc.        8-K:2,8,9   5/04/23   11:268K                                   Business Wire/FA
 5/04/23  Aldeyra Therapeutics, Inc.        10-Q        3/31/23   65:6.6M                                   Donnelley … Solutions/FA
 4/28/23  Aldeyra Therapeutics, Inc.        10-K/A     12/31/22   14:602K                                   Donnelley … Solutions/FA
 3/09/23  Aldeyra Therapeutics, Inc.        8-K:2,8,9   3/09/23   11:272K                                   Business Wire/FA
 3/09/23  Aldeyra Therapeutics, Inc.        10-K       12/31/22   77:12M                                    Donnelley … Solutions/FA
 3/02/23  Aldeyra Therapeutics, Inc.        8-K:8,9     3/02/23   11:188K                                   Business Wire/FA
 2/07/23  Aldeyra Therapeutics, Inc.        8-K:8,9     2/07/23   11:188K                                   Business Wire/FA
 5/01/20  Aldeyra Therapeutics, Inc.        8-K:5,9     4/30/20    2:124K                                   Donnelley … Solutions/FA
 3/12/20  Aldeyra Therapeutics, Inc.        10-K       12/31/19   77:8.2M                                   ActiveDisclosure/FA
 5/07/14  Aldeyra Therapeutics, Inc.        8-K:5,9     5/06/14    3:137K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-23-270467   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 17, 12:54:48.2pm ET